Who
Emily Luisa Hill
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Replimune Group; Chief Financial Officer, PTC Therapeutics.
In numbers
- Trades disclosed
- 61
- Buys
- 0
- Sells
- 25
- Bought
- $0
- Sold
- $3.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 31 May 2019
- Last trade
- 17 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 19 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $132K9,256 at $14.28 | filing |
| 17 Aug 2026filed 19 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $132K9,256 at $14.28 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $148K11,448 at $12.97 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $148K11,448 at $12.97 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $40K7,812 at $5.08 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $40K7,812 at $5.08 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 19 Dec 2025filed 19 Dec 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 15 Aug 2025filed 19 Aug 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $49K9,154 at $5.37 | filing |
| 20 May 2025filed 22 May 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $20K2,535 at $8.05 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 16 Aug 2024filed 19 Aug 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $91K8,938 at $10.18 | filing |
| 1 Apr 2024filed 3 Apr 2024 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —26,665 at $0.00 | filing |
| 18 Sep 2023filed 20 Sep 2023 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 18 Sep 2023filed 20 Sep 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —83,330 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.